Lamina Therapeutics is a clinical-stage platform technology company based in Strasbourg, France, whose mission is to innovate in bone and cartilage repair.

After 10 years of research at the University of Strasbourg and INSERM, the company was officially founded in 2020 to commercialize its innovative nanotechnology platform technology, developed by Professor Nadia Jessel. 

Lamina's lead product, lamina.ONE, is the only functionalized membrane with a controlled release mechanism of growth hormones and seeded with stem cells, offering a hybrid therapeutic action for the repair of cartilage as well as subchondral bone. No other product yet offers this comprehensive approach leading to a complete restoration of the patient's joint function.  

Lamina.ONE's nanostructured platform technology can control the delivery of multiple therapeutic agents in combination with different cells to accelerate tissue regeneration for multiple applications.